What will AbbVie stock be worth in 2030? (2024)

What will AbbVie stock be worth in 2030?

Average Price Target

Based on 17 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $180.80 with a high forecast of $200.00 and a low forecast of $135.00. The average price target represents a 6.35% change from the last price of $170.00.

How high can AbbVie stock go?

Average Price Target

Based on 17 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $180.80 with a high forecast of $200.00 and a low forecast of $135.00. The average price target represents a 6.35% change from the last price of $170.00.

Where will Abbv stock be in 5 years?

AbbVie stock price stood at $167.90

According to the latest long-term forecast, AbbVie price will hit $200 by the middle of 2025 and then $250 by the middle of 2027. AbbVie will rise to $300 within the year of 2028, $350 in 2030, $400 in 2033 and $450 in 2035.

What is AbbVie stock price forecast 2024?

According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024.

What is the stock price forecast for ABT in 2025?

What is the Abbott Laboratories stock prediction for 2025? According to our Abbott Laboratories stock prediction for 2025, ABT stock will be priced at $ 124.32 in 2025. This forecast is based on the stock's average growth over the past 10 years.

Is AbbVie a good long term buy?

The financial health and growth prospects of ABBV, demonstrate its potential to outperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.

Is AbbVie a good long term stock?

In terms of dividend growth, the company's current annualized dividend of $6.20 is up 4.7% from last year. In the past five-year period, AbbVie has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.28%.

What is the future of AbbVie?

Analyst Future Growth Forecasts

Earnings vs Market: ABBV's earnings (23.1% per year) are forecast to grow faster than the US market (13.5% per year). High Growth Earnings: ABBV's earnings are expected to grow significantly over the next 3 years.

What is AbbVie stock price forecast for 12 months?

Stock Price Forecast

The 11 analysts with 12-month price forecasts for AbbVie stock have an average target of 182.18, with a low estimate of 150 and a high estimate of 196. The average target predicts an increase of 8.51% from the current stock price of 167.90.

Is ABBV undervalued?

AbbVie Inc. (NYSE:ABBV) has made a decent recovery this year, jumping 11%. However, no good deed goes unpunished on Wall Street, so it still represents an underdog of the market as, even now, it trades at a valuation even lower than the average price-earnings ratio of the industry.

Why is AbbVie a good stock?

The company is still going strong. It currently offers a yield of 3.55%, and its cash payout ratio remains conservative at 42.13%. That leaves ample room for more dividend hikes. Here's the bottom line: Whether for growth or dividends, AbbVie is still an excellent stock to buy.

How much did AbbVie stock cost in 2013?

The stock debuted on Jan. 2, 2013, as a spin-off from Abbott Labs, and it was priced at $35. If you'd invested $25,000 into the company then, that would have secured you about 714 shares of the healthcare business.

How many times a year does AbbVie pay dividends?

( ABBV ) pays dividends on a quarterly basis. The next dividend payment is planned on May 15, 2024 . AbbVie Inc. ( ABBV ) has increased its dividends for 10 consecutive years.

Should I sell ABT stock?

Abbott Labs's analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

Is ABT a blue chip stock?

These stable stalwarts represent some of the best no-brainer blue-chip stocks to buy. Apple (AAPL): Apple brings relevance and strong value to the table. Microsoft (MSFT): The business world runs on Microsoft. Abbott Laboratories (ABT): Abbott enjoys excellent profitability margins.

What is the stock price forecast for ABT 5 year?

On average, Wall Street analysts predict that Abbott Laboratories's share price could reach $125.33 by Apr 3, 2025. The average Abbott Laboratories stock price prediction forecasts a potential upside of 12.63% from the current ABT share price of $111.28.

Is AbbVie a safe stock?

AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.5% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.

What is special about AbbVie?

We are making significant advancements with a robust pipeline of potential new medicines as we look to find the treatments of tomorrow. We are driven by our compassion for people, commitment to innovation and inclusion, service to the community and uncompromising integrity.

Does AbbVie have too much debt?

We'd say that AbbVie's moderate net debt to EBITDA ratio ( being 1.7), indicates prudence when it comes to debt. And its commanding EBIT of 10.8 times its interest expense, implies the debt load is as light as a peaco*ck feather.

Does Warren Buffett own AbbVie stock?

Buffett owned shares of AbbVie (ABBV 0.97%) in Berkshire's portfolio not too long ago. He subsequently exited his positions in AbbVie and several other big pharma stocks. However, the legendary investor nonetheless still has a stake in AbbVie through NEAM.

Who is the largest shareholder of AbbVie?

Does AbbVie pay monthly dividends?

(NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable May 15, 2024, to stockholders of record at the close of business on April 15, 2024. Since the company's inception in 2013, AbbVie has increased its dividend by more than 285 percent.

Who is AbbVie buying?

(NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

What was the problem with AbbVie?

CHICAGO – A nationwide class of consumers sued AbbVie, alleging the pharmaceutical company engaged in a fraudulent scheme to inflate the cost of the highest-grossing drug in the world, Humira, by 470% over the last two decades, according to attorneys at Hagens Berman and Carella Byrne Cecchi Brody Agnello.

What is the AbbVie controversy?

In 2018, AbbVie agreed to pay $25 million to resolve allegations that it made use of kickback schemes to promote its cholesterol drug Tricor. In 2020, AbbVie agreed to pay $24M to resolve allegations that it made use of kickback schemes to promote its rheumatoid arthritis drug Humira using "nurse ambassadors".